ENGAGE | CONNECT | LEARN
4.5 hours of CME/CE credits for the entire care team
Why Attend
Join oncology experts and connect with your clinical care community to discover the most accurate recommendations for treating patients with hepatocellular carcinoma (HCC). Experience the opportunity to master the use of current and emerging immunotherapy agents in combination, in succession, and sequentially with interventional arterially directed therapy (ADT).
You'll have the opportunity to participate in multiple activities, including:
- A multidisciplinary HCC tumor board panel ready to lead you through challenging cases
- Breakout sessions delving into tissue sample issues, and treatment options for early, intermediate, and advanced HCC
- Guidance on patient counseling and shared decision-making
CME Information
Agenda
Tumor Board: 60 minutes
Breakout Sessions: 120 minutes
- HCC Diagnostic, Tissue Acquisition and Interpretation Challenges
- Treatment for Early and Intermediate HCC
- Treatment for Advanced HCC
- Patient Perspectives
Problem-Based Learning–HCC Patient Cases: 60 minutes
Case Summary and Action Plan Development: 30 minutes
Learning Objectives
Target Audience
Summit Partners
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by The France Foundation. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Commercial Support Acknowledgement
CME Information
Agenda
Tumor Board: 60 minutes
Breakout Sessions: 120 minutes
- HCC Diagnostic, Tissue Acquisition and Interpretation Challenges
- Treatment for Early and Intermediate HCC
- Treatment for Advanced HCC
- Patient Perspectives
Problem-Based Learning–HCC Patient Cases: 60 minutes
Case Summary and Action Plan Development: 30 minutes
Learning Objectives
Target Audience
Accredited Provider
Accreditation Statement
Commercial Support Acknowledgement
Expert Faculty Steering Committee
Adam Burgoyne, MD, PhD
Chair of the Steering Committee
Associate Clinical Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Diego
San Diego, California
Chair of the Steering Committee
Associate Clinical Professor
Department of Medicine
Division of Hematology/Oncology
University of California, San Diego
San Diego, California
Rony Avritscher, MD, FSIR
Department of Interventional Radiology
Professor of Interventional Radiology
MD Anderson Cancer Center
Houston, Texas
Cindi Cantril MPH, RN, OCN, CBCN
Cancer Resources Recovery
Geyersville, California
Jingmei Lin, MD, PhD
Professor of Pathology & Laboratory Medicine
Indiana University Health
Indianapolis, Indiana
Professor of Pathology & Laboratory Medicine
Indiana University Health
Indianapolis, Indiana
Sarah Manes, MS, CCLS
Liver Cancers Program Director
Global Liver Institute
Liver Cancers Program Director
Global Liver Institute
Isabel Newton, MD, PhD
Department of Radiology
Assistant Professor of Radiology
University of California, San Diego
San Diego, California
Department of Radiology
Assistant Professor of Radiology
University of California, San Diego
San Diego, California
Amit Singal, MD
Medical Director of the Liver Tumor Program
Clinical Chief of Hepatology
Professor of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas
Medical Director of the Liver Tumor Program
Clinical Chief of Hepatology
Professor of Internal Medicine
UT Southwestern Medical Center
Stacey Stein, MD
Associate Professor of Internal Medicine
Assistant Medical Director, Clinical Trials Office
Yale Medicine
New Haven, Connecticut
This CME/CE event is presented in collaboration with the following organizations:
